AZITHROMYCIN - THE FIRST OF THE TISSUE-SELECTIVE AZALIDES

被引:66
作者
HOEPELMAN, IM [1 ]
SCHNEIDER, MME [1 ]
机构
[1] UNIV UTRECHT HOSP, EIJKMAN WINKLER LAB MED MICROBIOL, UTRECHT, NETHERLANDS
关键词
AZALIDES; AZITHROMYCIN; MICROBIOLOGY; PHARMACOKINETICS; CLINICAL USE; SAFETY; DRUG INTERACTION;
D O I
10.1016/0924-8579(95)00009-W
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The azalide azithromycin, which is derived from erythromycin, contains a methyl-substituted nitrogen in the lactone ring. This 15-membered expanded lactone ring results in improved acid stability and oral bioavailability compared with erythromycin. Azithromycin possesses a broad spectrum of activity against Gram-positive and Gram-negative bacteria, including enhanced activity compared with the macrolides against Haemophilus influenzae and Moraxella catarrhalis. In vitro activity of azithromycin against intracellular and clinically atypical pathogens is also good. Azithromycin has a distinct pharmacokinetic profile compared with other antimicrobial agents, the most prominent feature is its high tissue selectivity. Concentrations of azithromycin in respiratory tract, gynaecological tissue and prostate remain above minimum inhibitory concentrations of pathogens for several days, thus making it possible to use a short-course, once-daily dosing regimen. Another feature of azithromycin is that it rapidly penetrates phagocytic cells, with the release of the antibiotics at local sites of infection. Comparative clinical trials have shown that azithromycin given once daily for 3 or 5 days is comparable to comparator drugs given for 7 or 10 days in the treatment of otitis media, sinusitis, pharyngitis, acute bronchitis, acute infectious exacerbations of chronic bronchitis, community-acquired pneumonia and skin and soft tissue infections in adults. Azithromycin given once daily for 3 days has also been shown to be effective in the treatment of respiratory tract and skin and soft tissue infections in children. In addition, some sexually-transmitted diseases are effectively treated by a single 1-g dose of azithromycin; clinical and microbiological responses were comparable to those recorded using doxycycline given twice daily for 7 days. The short-duration, once-daily dosing regimen is well tolerated in adults and children, and there is no evidence of interaction between azithromycin and theophylline, terfenadine, or cimetidine.
引用
收藏
页码:145 / 167
页数:23
相关论文
共 174 条
  • [1] COMPARISON OF THE EFFECTS OF THE NEW AZALIDE ANTIBIOTIC, AZITHROMYCIN, AND ERYTHROMYCIN ESTOLATE ON RAT-LIVER CYTOCHROME-P-450
    AMACHER, DE
    SCHOMAKER, SJ
    RETSEMA, JA
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (06) : 1186 - 1190
  • [2] PRECLINICAL TOXICOLOGY STUDIES WITH AZITHROMYCIN - GENETIC TOXICOLOGY EVALUATION
    AMACHER, DE
    ELLIS, JH
    JOYCE, AJ
    MUEHLBAUER, PA
    TURNER, GN
    WAHRENBURG, MG
    HOLDEN, HE
    RAY, VA
    [J]. MUTATION RESEARCH, 1993, 300 (02): : 79 - 90
  • [3] ONCE-DAILY AZITHROMYCIN IN THE TREATMENT OF ADULT SKIN AND SKIN-STRUCTURE INFECTIONS
    AMAYATAPIA, G
    AGUIRREAVALOS, G
    ANDRADEVILLANUEVA, J
    PEREDOGONZALEZ, G
    MORFINOTERO, R
    ESPARZAAHUMADA, S
    RODRIGUEZNORIEGA, E
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 31 : 129 - 135
  • [4] AZITHROMYCIN, A MACROLIDE ANTIBIOTIC WITH POTENT ACTIVITY AGAINST TOXOPLASMA-GONDII
    ARAUJO, FG
    GUPTILL, DR
    REMINGTON, JS
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (05) : 755 - 757
  • [5] ARAUJO FG, 1989, CHEMOTHER INFECT S1, V1, P11
  • [6] ARGUEDAS AG, 18TH INT C CHEM
  • [7] INVITRO ACTIVITY OF ERYTHROMYCIN, ROXITHROMYCIN AND CP-62993 AGAINST COMMON PEDIATRIC PATHOGENS
    ARONOFF, SC
    LAURENT, C
    JACOBS, MR
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1987, 19 (02) : 275 - 276
  • [8] PROPHYLACTIC AND THERAPEUTIC ACTIVITIES OF AZITHROMYCIN IN A MOUSE MODEL OF PNEUMOCOCCAL PNEUMONIA
    AZOULAYDUPUIS, E
    VALLEE, E
    BEDOS, JP
    MUFFATJOLY, M
    POCIDALO, JJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (06) : 1024 - 1028
  • [9] RANDOMIZED CONTROLLED TRIAL OF SINGLE-DOSE AZITHROMYCIN IN TREATMENT OF TRACHOMA
    BAILEY, RL
    ARULLENDRAN, P
    WHITTLE, HC
    MABEY, DCW
    [J]. LANCET, 1993, 342 (8869) : 453 - 456
  • [10] BALDWIN DR, 1990, EUR RESPIR J, V3, P886